Options Contract Analysis and Investment Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy A?
Source: NASDAQ.COM
- Put Option Appeal: The current bid for the $115.00 put option is $9.80, and if an investor sells this contract, they commit to buying the stock at $115.00, effectively lowering their cost basis to $105.20, which represents an approximately 8% discount compared to the current price of $124.38, making it attractive for potential buyers.
- Yield Potential Analysis: Should the put option expire worthless, it would yield an 8.52% return on cash commitment, or 8.04% annualized, referred to as YieldBoost, highlighting the potential attractiveness of this contract.
- Call Option Returns: The $130.00 call option has a current bid of $14.20, and if an investor buys shares at $124.38 and sells this call, they could achieve a total return of 15.94% if the stock is called away at March 2027 expiration, showcasing the potential profitability of this strategy.
- Risk Assessment: Current analytics suggest a 68% chance that the $115.00 put option will expire worthless, while the $130.00 call option has a 45% chance of doing so, indicating that investors should monitor these probabilities over time to make informed investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 118.170
Low
160.00
Averages
171.67
High
180.00
Current: 118.170
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AGILENT TECHNOLOGIES INC: UBS Lowers Price Target to $165 from $180
Company Overview: Agile Technologies is involved in the tech sector, focusing on innovative solutions and products.
Stock Price Update: The target price for Agile Technologies has been adjusted to $165, down from the previous $180.
See More
Agilent Technologies Sets FY26 Revenue Target Amid Q1 Disappointment
- Fiscal Year Revenue Target: Agilent Technologies has set a revenue target of $7.3 billion to $7.5 billion for FY26, indicating confidence in future growth despite disappointing Q1 results.
- Margin Growth Strategy: The company is expanding its Ignite Operating System to enhance margins, aiming to address market challenges and strengthen its competitive position through improved operational efficiency.
- EPS Guidance Increase: Despite the disappointing Q1 performance, Agilent has raised its fiscal 2026 EPS guidance, reflecting management's optimistic outlook for subsequent performance.
- Market Reaction: Given the Q1 results falling short of market expectations, Agilent's stock price may face pressure, prompting investors to monitor how the company executes its growth strategy to restore market confidence.
See More
Agilent Technologies Q1 2026 Earnings Call Insights
- Revenue Growth: Agilent Technologies reported $1.8 billion in revenue for Q1 2026, achieving a core growth rate of 4.4%, despite a $10 million revenue impact from the winter storm in late January, most of which was recovered by early February, demonstrating the company's resilience in adversity.
- Gross Margin and Operational Efficiency: The Q1 gross margin stood at 53.7%, down 100 basis points year-over-year primarily due to tariff pressures, while the operating margin was 24.6%, in line with expectations, establishing a solid foundation for the remainder of the fiscal year, indicating the company's efforts in cost control.
- Future Outlook and Guidance: The company expects revenue for FY26 to range between $7.3 billion and $7.5 billion, with core growth projected at 4% to 6%, and earnings per share anticipated between $5.90 and $6.04, reflecting confidence in market demand and positive currency impacts.
- Innovation and Market Dynamics: Agilent achieved a 7% growth in the pharma sector, with double-digit growth in biotech and a remarkable 50% increase in GLP-1 products, showcasing the company's strong competitive position in rapidly growing markets.
See More
Agilent (A) Q1 2026 Earnings Call Transcript
See More
Agilent's Q1 2026 Results Miss Estimates Despite EPS Guidance Raise
- Disappointing Performance: Agilent's Q1 2026 non-GAAP EPS of $1.36, while up from $1.31 year-over-year, fell short of the $1.37 consensus estimate, indicating pressure on the company's profitability.
- Revenue Outlook Raised: Despite the earnings miss, Agilent raised its fiscal 2026 revenue guidance to $7.3B-$7.5B from $7.3B-$7.4B, reflecting confidence in future growth prospects amid current challenges.
- Cash Flow Status: As of January 31, 2026, Agilent reported cash and cash equivalents of approximately $1.76B, down from $1.79B on October 31, 2025, suggesting challenges in liquidity management.
- Market Reaction: Following the earnings report, Agilent's stock fell about 3% in after-hours trading, reflecting investor disappointment over the earnings miss, which may impact the company's future market performance.
See More
Agilent Technologies Reports Decline in Q1 Earnings
- Earnings Overview: Agilent Technologies reported a first-quarter net income of $305 million, or $1.07 per share, down from $318 million and $1.11 per share last year, indicating pressure on the company's profitability.
- Revenue Growth: Despite the decline in net income, the company's revenue increased by 7% to $1.798 billion from $1.681 billion last year, suggesting that the company still possesses growth potential in sales.
- Adjusted Earnings: Excluding items, Agilent's adjusted earnings were $386 million, or $1.36 per share, reflecting stability in the core business despite an overall decline in profitability.
- Future Guidance: The company provided guidance for next quarter's EPS in the range of $1.39 to $1.42, and full-year EPS guidance of $5.90 to $6.04, indicating a cautiously optimistic outlook from management regarding future performance.
See More
AGILENT TECHNOLOGIES INC: UBS Lowers Price Target to $165 from $180
Company Overview: Agile Technologies is involved in the tech sector, focusing on innovative solutions and products.
Stock Price Update: The target price for Agile Technologies has been adjusted to $165, down from the previous $180.
See More
Agilent Technologies Sets FY26 Revenue Target Amid Q1 Disappointment
- Fiscal Year Revenue Target: Agilent Technologies has set a revenue target of $7.3 billion to $7.5 billion for FY26, indicating confidence in future growth despite disappointing Q1 results.
- Margin Growth Strategy: The company is expanding its Ignite Operating System to enhance margins, aiming to address market challenges and strengthen its competitive position through improved operational efficiency.
- EPS Guidance Increase: Despite the disappointing Q1 performance, Agilent has raised its fiscal 2026 EPS guidance, reflecting management's optimistic outlook for subsequent performance.
- Market Reaction: Given the Q1 results falling short of market expectations, Agilent's stock price may face pressure, prompting investors to monitor how the company executes its growth strategy to restore market confidence.
See More
Agilent Technologies Q1 2026 Earnings Call Insights
- Revenue Growth: Agilent Technologies reported $1.8 billion in revenue for Q1 2026, achieving a core growth rate of 4.4%, despite a $10 million revenue impact from the winter storm in late January, most of which was recovered by early February, demonstrating the company's resilience in adversity.
- Gross Margin and Operational Efficiency: The Q1 gross margin stood at 53.7%, down 100 basis points year-over-year primarily due to tariff pressures, while the operating margin was 24.6%, in line with expectations, establishing a solid foundation for the remainder of the fiscal year, indicating the company's efforts in cost control.
- Future Outlook and Guidance: The company expects revenue for FY26 to range between $7.3 billion and $7.5 billion, with core growth projected at 4% to 6%, and earnings per share anticipated between $5.90 and $6.04, reflecting confidence in market demand and positive currency impacts.
- Innovation and Market Dynamics: Agilent achieved a 7% growth in the pharma sector, with double-digit growth in biotech and a remarkable 50% increase in GLP-1 products, showcasing the company's strong competitive position in rapidly growing markets.
See More
Agilent (A) Q1 2026 Earnings Call Transcript
See More
Agilent's Q1 2026 Results Miss Estimates Despite EPS Guidance Raise
- Disappointing Performance: Agilent's Q1 2026 non-GAAP EPS of $1.36, while up from $1.31 year-over-year, fell short of the $1.37 consensus estimate, indicating pressure on the company's profitability.
- Revenue Outlook Raised: Despite the earnings miss, Agilent raised its fiscal 2026 revenue guidance to $7.3B-$7.5B from $7.3B-$7.4B, reflecting confidence in future growth prospects amid current challenges.
- Cash Flow Status: As of January 31, 2026, Agilent reported cash and cash equivalents of approximately $1.76B, down from $1.79B on October 31, 2025, suggesting challenges in liquidity management.
- Market Reaction: Following the earnings report, Agilent's stock fell about 3% in after-hours trading, reflecting investor disappointment over the earnings miss, which may impact the company's future market performance.
See More
Agilent Technologies Reports Decline in Q1 Earnings
- Earnings Overview: Agilent Technologies reported a first-quarter net income of $305 million, or $1.07 per share, down from $318 million and $1.11 per share last year, indicating pressure on the company's profitability.
- Revenue Growth: Despite the decline in net income, the company's revenue increased by 7% to $1.798 billion from $1.681 billion last year, suggesting that the company still possesses growth potential in sales.
- Adjusted Earnings: Excluding items, Agilent's adjusted earnings were $386 million, or $1.36 per share, reflecting stability in the core business despite an overall decline in profitability.
- Future Guidance: The company provided guidance for next quarter's EPS in the range of $1.39 to $1.42, and full-year EPS guidance of $5.90 to $6.04, indicating a cautiously optimistic outlook from management regarding future performance.
See More
